200 completed. 200 Phase 3, 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 200 | Completed 200 |
| Phase 2 | 19 | Completed 19 |
Follow Headache Disorders, Primary: new trials by email Literature Review of Headache Disorders, Primary trials Research Report on Headache Disorders, Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zonisamide Versus Topiramate in Migraine Zonisamide 50 MG, Topiramate 50 MG - Migraine | Phase 3 | Completed | Kafrelsheikh University | 600 | 2024-04-01 | 2026-05-27 |
| Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine Atogepant, Placebo for Atogepant - Migraine | Phase 3 | Completed | AbbVie | 2158 | 2024-03-25 | 2026-09-11 |
| A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults Zavegepant, Placebo - Migraine | Phase 3 | Completed | Pfizer | 1414 | 2023-11-29 | 2026-05-22 |
| Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine Atogepant, Placebo for Atogepant, Topiramate - Migraine | Phase 3 | Completed | AbbVie | 545 | 2023-10-07 | 2026-07-02 |
| Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) Click Digital Therapeutic - Migraine, Episodic Migraine | Phase 3 | Completed | Click Therapeutics, Inc. | 110 | 2023-07-21 | 2024-12-18 |
| Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine Atogepant, Placebo for Atogepant - Migraine | Phase 3 | Completed | AbbVie | 524 | 2023-07-12 | 2026-06-11 |
| Comparison of Ketorolac at Three Doses in Children With Acute Pain Ketorolac Tromethamine - Acute Pain, Abdominal Pain | Phase 3 | Completed | Hamilton Health Sciences Corporation | 171 | 2023-06-01 | 2025-07-09 |
| A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. Rimegepant, Placebo - Migraine | Phase 3 | Completed | Pfizer | 787 | 2023-05-15 | 2026-09-03 |
| Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine Rizatriptan 10 mg + Naproxen 550mg, Maxalt 10Mg Tablet, Flanax 550mg - Migraine | Phase 3 | Completed | Eurofarma Laboratorios S.A. | 2068 | 2022-12-30 | 2026-10-26 |
| Botulinum Toxin A in Frequent and Chronic Tension-type Headache Botulinum Toxin Type A in saline water, Isotone saline water - Tension-Type Headache | Phase 3 | Completed | Helse Nord-Trøndelag HF | 66 | 2022-10-03 | 2025-03-13 |
| A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 365 | 2022-09-30 | 2025-11-26 |
| Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) AXS-07 (meloxicam-rizatriptan) - Migraine | Phase 3 | Completed | Axsome Therapeutics, Inc. | 100 | 2022-08-31 | 2025-12-02 |
| Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only) Rimegepant, Placebo - Migraine | Phase 3 | Completed | Pfizer | 496 | 2022-08-09 | 2025-11-18 |
| Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only) Rimegepant 25 MG, Rimegepant 75 MG, Placebo - Migraine | Phase 3 | Completed | Pfizer | 897 | 2022-08-09 | 2025-03-07 |
| Lacosamide Versus Propranolol in Migraine Lacosamide tablet, Propranolol - Migraine Disorders | Phase 3 | Completed | Kafrelsheikh University | 600 | 2022-06-01 | 2024-05-01 |
| The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients Lacosamide 50 MG Oral Tablet, Ibuprofen 400 mg - Effect of Drug, Migraine Disorders | Phase 3 | Completed | Kafrelsheikh University | 200 | 2022-06-01 | 2024-03-21 |
| A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants Rimegepant 75mg Orally Disintegrating Tablets (ODT) - Acute Migraine | Phase 3 | Completed | Pfizer | 241 | 2022-05-19 | 2025-02-20 |
| Valproate Versus Topiramate in Migraine Valproic acid, Topiramate 50 MG - Migraine Disorders | Phase 3 | Completed | Kafrelsheikh University | 600 | 2022-05-01 | 2024-07-15 |
| Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine Atogepant - Chronic Migraine | Phase 3 | Completed | AbbVie | 75 | 2022-03-22 | 2026-06-16 |
| A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents Ketorolac, Metoclopramide, Active Remote Electrical Neuromodulation Device - Migraine Disorders | Phase 3 | Completed | University of Calgary | 22 | 2022-02-22 | 2025-03-12 |
Showing 20 of 200. Sign in to see all of them.
Migraine Disorders (181) · Headache (45) · Migraine with Aura (13) · Migraine without Aura (13) · Cluster Headache (12) · Epilepsy (6) · Bronchiolitis Obliterans Syndrome (5) · Pain (5) · Tension-Type Headache (5) · Headache Disorders (4) · Hyperacusis (3) · Photophobia (3) · Dysmenorrhea (2) · Emergencies (2) · Nausea (2)
Brain Diseases (199) · Central Nervous System Diseases (199) · Nervous System Diseases (199) · Headache Disorders (196) · Pathological Conditions, Signs and Symptoms (54) · Signs and Symptoms (51) · Neurologic Manifestations (50) · Pain (43) · Trigeminal Autonomic Cephalalgias (11) · Pathologic Processes (8) · Migraine Disorders (6) · Bronchial Diseases (5) · Bronchiolitis (5) · Bronchiolitis Obliterans (5)
Sumatriptan (21) · rizatriptan (17) · Topiramate (16) · Naproxen (15) · eptinezumab (10) · fremanezumab (10) · rimegepant sulfate (10) · atogepant (8) · galcanezumab (8) · Botulinum Toxins, Type A (7) · Sodium Chloride (7) · erenumab (7) · Valproic Acid (5) · telcagepant (5) · Acetaminophen (4)
Pfizer (15) · GlaxoSmithKline (13) · Organon and Co (13) · Allergan (11) · Eli Lilly and Company (10) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (9) · H. Lundbeck A/S (7) · Merck Sharp & Dohme LLC (6) · Teva Branded Pharmaceutical Products R&D, Inc. (6) · AbbVie (5) · Amgen (4) · Axsome Therapeutics, Inc. (4) · Kafrelsheikh University (4) · Otsuka Pharmaceutical Co., Ltd. (4) · Abbott (3)
United States (110) · Germany (24) · Spain (23) · Canada (20) · Japan (20) · United Kingdom (19) · Belgium (18) · Italy (17) · France (16) · Czechia (15) · Finland (15) · Netherlands (15) · Denmark (14) · Poland (14) · Hungary (12)
Takehisa Matsumaru (4) · Adele Thorpe (3) · David Taylor (3) · Detlef Albrecht, MD (3)
PMID 39982105, PMID 11914403, PMID 12807523, PMID 35978286, PMID 11284464, PMID 31482569, PMID 31952501, PMID 32576229, PMID 33781209, PMID 34264500, PMID 34874514, PMID 35076090, PMID 36125279, PMID 36739511, PMID 38462625, PMID 39648629, PMID 41652666, PMID 42839212, PMID 8984084, PMID 17405970, PMID 19546766, PMID 20353434, PMID 20487038, PMID 20855373, PMID 21521204, PMID 21883197, PMID 24579886, PMID 25080874, PMID 25500317, PMID 30462830, PMID 30594122, PMID 30942898, PMID 31112399, PMID 31253091, PMID 33026630, PMID 33026631, PMID 33069214, PMID 33142014, PMID 33143451, PMID 33241721, PMID 33413075, PMID 33544305, PMID 33549036, PMID 33608814, PMID 33874756, PMID 33942560, PMID 33950375, PMID 34049484, PMID 34819017, PMID 34823467
2015 (8), 2019 (4), 2014 (3), 2018 (3), 2023 (2), 2005 (1), 2008 (1), 2016 (1)